Browsing Bergen Open Research Archive by Author "Torkildsen, Øivind"

Now showing items 1-18 of 18

    • Alpha-tocopherol and MRI outcomes in multiple sclerosis - association and prediction 

      Løken-Amsrud, Kristin Ingeleiv; Myhr, Kjell-Morten; Bakke, Søren Jacob; Beiske, Antonie Giæver; Bjerve, Kristian S; Bjørnarå, Bård T.; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Saltyte Benth, Jurate; Torkildsen, Øivind; Wergeland, Stig; Holmøy, Trygve (Peer reviewed; Journal article, 2013-01-22)
      Objective: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship ...

    • Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model 

      Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten; Aksnes, Lage; Mørk, Sverre; Bø, Lars (Peer reviewed; Journal article, 2011-10-20)
      Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It is not known to what extent this effect is due to a modulation of ...

    • Disease-modifying treatments for multiple sclerosis – a review of approved medications 

      Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2015-11-13)
      Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing remitting MS (RRMS). ...

    • Environmental risk factors for multiple sclerosis. Results from animal and human studies on diet, vitamin D and Epstein-Barr virus 

      Torkildsen, Øivind (Doctoral thesis, 2010-01-19)
      Multiple Sclerosis (MS) is an immune mediated disease of the central nervous system (CNS). The aetiology is unknown, but environmental factors as well as multiple separate genetic loci contribute to the disease susceptibility. ...

    • Fingolimod does not enhance cerebellar remyelination in the cuprizone model 

      Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars; Myhr, Kjell-Morten; Vedeler, Christian A.; Wergeland, Stig; Torkildsen, Øivind (Journal article, 2015-08)
      Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected ...

    • In-depth cerebrospinal fluid quantitative proteome and deglycoproteome analysis: presenting a comprehensive picture of pathways and processes affected by multiple sclerosis 

      Kroksveen, Ann Cathrine; Guldbrandsen, Astrid; Vaudel, Marc; Lereim, Ragnhild Reehorst; Barsnes, Harald; Myhr, Kjell-Morten; Torkildsen, Øivind; Berven, Frode (Peer reviewed; Journal article, 2017)
      In the current study, we conducted a quantitative in-depth proteome and deglycoproteome analysis of cerebrospinal fluid (CSF) from relapsing-remitting multiple sclerosis (RRMS) and neurological controls using mass spectrometry ...

    • Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity 

      Holmøy, Trygve; Løken-Amsrud, Kristin Ingeleiv; Bakke, Jacob; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Saltyte Benth, Jurate; Torkildsen, Øivind; Wergeland, Stig; Myhr, Kjell-Morten; Michelsen, Annika; Aukrust, Pål; Ueland, Thor (Peer reviewed; Journal article, 2013-09-19)
      Background. Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the ...

    • Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study 

      Bjørnevik, Kjetil; Riise, Trond; Benjaminsen, Espen; Celius, Elisabeth Gulowsen; Dahl, Ole-Petter; Kampman, Margitta Theodora; Løken-Amsrud, Kristin Ingeleiv; Midgard, Rune; Myhr, Kjell-Morten; Torkildsen, Øivind; Vatne, Anita; Grytten, Nina (Peer reviewed; Journal article, 2017)
      Background: The conflicting results from studies on socioeconomic status (SES) and multiple sclerosis (MS) risk might be due to a change in the distribution of environmental exposures over time or to methodological limitations ...

    • Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis 

      Wesnes, Kristin; Myhr, Kjell-Morten; Riise, Trond; Stokke, Silje Agnethe; Torkildsen, Øivind; Wergeland, Stig; Holmøy, Trygve; Midgard, Rune; Bru, Alla Nikolajevna S; Edland, Astrid; Eikeland, Randi; Gosal, Sonia; Harbo, Hanne Flinstad; Kleveland, Grethe; Sørenes, Yvonne; Øksendal, Nina; Bjørnevik, Kjetil Lauvland (Journal article; Peer reviewed, 2021)
      Background: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains unclear. ...

    • Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model 

      Fjær, Sveinung; Bø, Lars; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig (Peer reviewed; Journal article, 2015-03-02)
      Magnetization transfer ratio (MTR) is a magnetic resonance imaging (MRI) method which may detect demyelination not detected by conventional MRI in the central nervous system of patients with multiple sclerosis (MS). A ...

    • Neurofilament light chain as a biomarker in multiple sclerosis 

      Varhaug, Kristin Nielsen; Torkildsen, Øivind; Myhr, Kjell-Morten; Vedeler, Christian A. (Peer reviewed; Journal article, 2019-04-05)
      Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments ...

    • Neurofilament light chain predicts disease activity in relapsing-remitting MS 

      Varhaug, Kristin Nielsen; Barro, Christian; Bjørnevik, Kjetil Lauvland; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig; Bindoff, Laurence; Kuhle, Jens; Vedeler, Christian A. (Peer reviewed; Journal article, 2018)
      Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods: A cohort of 85 patients with RRMS were followed ...

    • No association of tobacco use and disease activity in multiple sclerosis 

      Kvistad, Silje; Myhr, Kjell-Morten; Holmøy, Trygve; Saltyte Benth, Jurate; Løken-Amsrud, Kristin Ingeleiv; Wergeland, Stig; Beiske, Antonie Giæver; Bjerve, Kristian S; Hovdal, Harald Olav; Lilleås, Finn; Midgard, Rune; Pedersen, Tom; Bakke, Søren Jacob; Torkildsen, Øivind (Peer reviewed; Journal article, 2016-08)
      Objective: To study whether tobacco use is associated with MRI and clinical disease activity in patients with multiple sclerosis (MS). Methods: Prospective cohort study of 87 patients with relapsing-remitting MS originally ...

    • Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder 

      Holmøy, Trygve; Høglund, Rune Alexander; Illes, Zsolt; Myhr, Kjell-Morten; Torkildsen, Øivind (Journal article; Peer reviewed, 2020)
      Background Treatment of neuromyelitis optica spectrum disorder (NMOSD) has so far been based on retrospective case series. The results of six randomized clinical trials including five different monoclonal antibodies ...

    • Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study 

      Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)
      Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ...

    • Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades 

      Grytten, Nina; Torkildsen, Øivind; Myhr, Kjell-Morten (Peer reviewed; Journal article, 2015-06-05)
      Norway has been subjected to numerous epidemiological investigations on the prevalence and incidence of multiple sclerosis (MS), dating back to 1935. The objective of this study was to review the studies on the prevalence ...

    • A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS 

      Skorve, Ellen; Lundervold, Astri; Torkildsen, Øivind; Myhr, Kjell-Morten (Journal article; Peer reviewed, 2020)
      Background: Cognitive impairment is common in patients with multiple sclerosis (MS) and may occur at any stage and with any subtype of the disease. Screening and monitoring of cognitive function should therefore be implemented ...

    • An Update on Vitamin D and Disease Activity in Multiple Sclerosis 

      Smolders, Joost; Torkildsen, Øivind; Camu, William; Holmøy, Trygve (Peer reviewed; Journal article, 2019)
      Vitamin D and its main active metabolite 1,25-dihydroxyvitamin D serve a crucial role in maintenance of a healthy calcium metabolism, yet have additional roles in immune and central nervous system cell homeostasis. Serum ...